DocGo Inc (DCGO)vsNovartis AG ADR (NVS)
DCGO
DocGo Inc
$0.67
+15.31%
HEALTHCARE · Cap: $61.74M
NVS
Novartis AG ADR
$154.61
-1.48%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 18690% more annual revenue ($56.69B vs $301.71M). NVS leads profitability with a 22.5% profit margin vs -62.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
DCGO
Hold36
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.4%
Fair Value
$2.10
Current Price
$0.67
$1.43 discount
Margin of Safety
-63.9%
Fair Value
$92.92
Current Price
$154.61
$61.69 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
DCGO profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.99 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 36/100), backed by strong 22.5% margins. DCGO offers better value entry with a 65.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a leading mobile healthcare service provider focused on enhancing patient accessibility and optimizing healthcare delivery through its cutting-edge logistics and telehealth solutions. The company specializes in urgent care, diagnostic testing, and health screenings, effectively addressing key healthcare challenges across diverse environments and significantly improving patient experiences. With a strong commitment to innovation and expanding access to healthcare, DocGo is well-positioned in the dynamic healthtech sector, making it an attractive investment opportunity for institutional investors interested in sustainable growth and impactful social contributions.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?